Learn More About Cochleate Technology
Matinas BioPharma’s mission is to transform the way potent medicines are delivered and administered.
MTNB
NYSE American
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.
| Candidate & Indication | Development Stage | ||||
|---|---|---|---|---|---|
| MAT2203 Prevention of IFI in Acute Lymphoblastic Leukemia |
IND Preparation Phase complete
|
Phase 1 Development Phase complete
|
Phase 2 Development Phase in progress
|
Phase 3 Development Phase not started
|
Market Phase not started
|
| MAT2501 Non-Tuberculous Mycobacterium (NTM) Infections |
IND Preparation Phase complete
|
Phase 1 Development Phase in progress
|
Phase 2 Development Phase not started
|
Phase 3 Development Phase not started
|
Market Phase not started
|
